Skip to content

Study · Randomized controlled trial · n = 25 · 2021

3 results

Semaglutide reduces fat accumulation in the tongue: A randomized single-blind, pilot study.

Jensterle M, Ferjan S, Vovk A, Battelino T, Rizzo M, Janež A

Diabetes research and clinical practice2 Jul 2021Cited by 36 (Europe PMC)

PMID34217774 (opens in a new tab)DOI10.1016/j.diabres.2021.108935 (opens in a new tab)PepBankPUB-34217774
Publisher pagePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In obese women with PCOS, semaglutide reduced tongue fat tissue volume versus placebo, which increased.

    In plain wordsIn obese women with PCOS, semaglutide reduced tongue fat compared with placebo.

    Peptide
    Semaglutide
    Outcome
    DecreaseTongue fat tissue volume change
    Study

    n = 25

    Comparator
    Placebo
    Outcome group
    Body composition · Metabolic and weight
    Studied dose
    1.0 mg · 16 weeksAs given in this study (human).

    Measurements

    Change in tongue fat tissue
    −1.94 cm3
    semaglutide
    Change in tongue fat tissue
    3.12 cm3
    placebo

    Source sentences

    Summary
    Tongue fat tissue and fat proportion significantly reduced after semaglutide vs placebo (-1.94 ± 5.51 vs. + 3.12 ± 4.87 cm3, p = 0.022
    2 context sentences
    Summary · context
    Twenty-five obese women with polycystic ovary syndrome (PCOS) (33.7 ± 5.3 years, body mass index (BMI) 36.1 ± 3.9 kg/m2, mean ± SD) were randomized to semaglutide 1.0 mg or placebo for 16 weeks.
    Summary · context
    We quantified tongue volume and its fat tissue and fat proportion by magnetic resonance imaging.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In obese women with PCOS, semaglutide reduced tongue fat proportion versus placebo.

    In plain wordsIn obese women with PCOS, semaglutide reduced the share of fat in the tongue compared with placebo.

    Peptide
    Semaglutide
    Outcome
    DecreaseTongue fat proportion change
    Study

    n = 25

    Comparator
    Placebo
    Outcome group
    Body composition · Metabolic and weight
    Studied dose
    1.0 mg · 16 weeksAs given in this study (human).

    Measurements

    Change in tongue fat proportion
    −0.02 NA
    semaglutide
    Change in tongue fat proportion
    0.04 NA
    placebo

    Source sentences

    Summary
    Tongue fat tissue and fat proportion significantly reduced after semaglutide vs placebo (-1.94 ± 5.51 vs. + 3.12 ± 4.87 cm3, p = 0.022, and -0.02 ± 0.07 vs. 0.04 ± 0.06, p = 0.010, respectively).
    2 context sentences
    Summary · context
    Twenty-five obese women with polycystic ovary syndrome (PCOS) (33.7 ± 5.3 years, body mass index (BMI) 36.1 ± 3.9 kg/m2, mean ± SD) were randomized to semaglutide 1.0 mg or placebo for 16 weeks.
    Summary · context
    We quantified tongue volume and its fat tissue and fat proportion by magnetic resonance imaging.
  3. 03HumanRandomized controlled trialMechanism

    In obese women with PCOS, the reductions in tongue fat were associated with reductions in body weight, BMI and waist circumference.

    In plain wordsIn obese women with PCOS, less tongue fat was linked to losing body weight, BMI and waist size.

    Peptide
    Semaglutide
    Outcome
    Not applicableCorrelation of tongue fat reductions with body weight, BMI and waist circumference reductions
    Study

    n = 25

    Comparator
    Placebo
    Outcome group
    Body composition · Metabolic and weight
    Studied dose
    1.0 mg · 16 weeksAs given in this study (human).

    Source sentences

    Summary
    Correlation analysis revealed that these reductions were associated with those in body weight, BMI and waist circumference (p = 0.010 for all).
    2 context sentences
    Summary · context
    Twenty-five obese women with polycystic ovary syndrome (PCOS) (33.7 ± 5.3 years, body mass index (BMI) 36.1 ± 3.9 kg/m2, mean ± SD) were randomized to semaglutide 1.0 mg or placebo for 16 weeks.
    Summary · context
    We quantified tongue volume and its fat tissue and fat proportion by magnetic resonance imaging.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:50 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.